---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Dosing and administration questions"
description: "Dosing and administration questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Premedication, Switching, Dosing, Administration, and Preparation. Questions: Does premedication help prevent Kesimpta injection reactions? What should be considered when switching to Kesimpta from another MS therapy? What is the Kesimpta dosage (dosing schedule)? How should patients schedule their first Kesimpta doses? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Dosing and administration questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Premedication

<a id="kesimpta-premedication"></a>

### Does premedication help prevent Kesimpta injection reactions?

> “Only limited benefit of premedication with corticosteroids, antihistamines, or acetaminophen was observed in RMS 
> clinical studies.”

Source: [KESIMPTA: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=4)

## Switching

<a id="kesimpta-switching-from-other-therapies"></a>

### What should be considered when switching to Kesimpta from another MS therapy?

> “When switching from therapies with immune effects, the duration and mechanism of action of these therapies should be 
> taken into account because of potential additive immunosuppressive effects when initiating KESIMPTA.”

Source: [KESIMPTA: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=7)

> “When initiating KESIMPTA after an immunosuppressive therapy or initiating an immunosuppressive therapy after 
> KESIMPTA, consider the potential for increased immunosuppressive effects [see Drug Interactions (7.1) and Clinical 
> Pharmacology (12.2)]. KESIMPTA has not been studied in combination with other MS therapies.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

## Dosing

<a id="kesimpta-dosage"></a>

### What is the Kesimpta dosage (dosing schedule)?

> “The recommended dosage of KESIMPTA is:  
> • 
> initial dosing of 20 mg by subcutaneous injection at Weeks 0, 1, and 2, followed by  
> • 
> subsequent dosing of 20 mg by subcutaneous injection once monthly starting at Week 4.”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

<a id="kesimpta-first-doses-schedule"></a>

### How should patients schedule their first Kesimpta doses?

> “Pick a day and start with 1 dose a week for the first 3 weeks. Skip the 4th week.
>
> Take your first monthly maintenance dose on the 5th week.
>
> Continue taking KESIMPTA once a month.”

Source: [KESIMPTA: Dosing & Administration, captured 2026-11-13](https://www.kesimptahcp.com/dosing-and-administration#:~:text=Pick%20a%20day%20and%20start,taking%20KESIMPTA%20once%20a%20month.)

> “Initial dosing of 20 mg by SC injection at weeks 0, 1, and 2, followed by subsequent dosing of 20 mg by SC injection once monthly starting at week 4.”

Source: [KESIMPTA: Dosing & Administration, captured 2026-11-13](https://www.kesimptahcp.com/dosing-and-administration#:~:text=Initial%20dosing%20of%2020%20mg,monthly%20starting%20at%20week%204.)

Note: These patient instructions count the first dosing week as the 1st week; the Prescribing Information numbers it Week 0, so its Week 4 is the 5th week here.

<a id="kesimpta-missed-dose"></a>

### What should patients do if a Kesimpta dose is missed?

> “If an injection of KESIMPTA is missed, it should be administered as soon as possible without waiting until the next 
> scheduled dose. Subsequent doses should be administered at the recommended intervals.”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

<a id="kesimpta-dose-selection"></a>

### Why was the 20 mg dose of Kesimpta chosen?

> “The KESIMPTA Phase 2 trial determined that once monthly frequency in a low SC dose was comparably effective, with fewer side effects, vs higher SC doses.<sup>4,5</sup>”

Source: [KESIMPTA: Dosing & Administration, captured 2026-11-13](https://www.kesimptahcp.com/dosing-and-administration#:~:text=The%20KESIMPTA%20Phase%202%20trial,side%20effects%2C%20vs%20higher%20SC)

> “The KESIMPTA (20 mg) dose was chosen through dose modeling based on B-cell depletion results and Phase 2 data.<sup>4,5</sup>”

Source: [KESIMPTA: Dosing & Administration, captured 2026-11-13](https://www.kesimptahcp.com/dosing-and-administration#:~:text=The%20KESIMPTA%20%2820%20mg%29%20dose,depletion%20results%20and%20Phase%202)

## Administration

<a id="kesimpta-first-injection"></a>

### Who should give the first Kesimpta injection?

> “The first injection of KESIMPTA should be performed under the guidance of a healthcare professional [see Warnings and 
> Precautions (5.2)].”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

> “As the first injection of KESIMPTA should be performed under the guidance of an HCP, it is up to the discretion of the HCP to determine how to monitor their patients.<sup>1</sup>”

Source: [KESIMPTA: FAQs, captured 2026-11-13](https://www.kesimptahcp.com/resources/faqs#:~:text=As%20the%20first%20injection%20of,determine%20how%20to%20monitor%20their)

On the page, select: What injection training support does Novartis offer?

<a id="kesimpta-injection-sites"></a>

### Where is Kesimpta injected?

> “KESIMPTA is intended for patient self-administration by subcutaneous injection.”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

> “Administer KESIMPTA in the abdomen, thigh, or outer upper arm subcutaneously. Do not give injection into moles, 
> scars, stretch marks, or areas where the skin is tender, bruised, red, scaly, or hard.”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

## Preparation

<a id="kesimpta-preparation"></a>

### How is Kesimpta prepared before injection?

> “Before administration, remove KESIMPTA Sensoready Pen or KESIMPTA prefilled syringe from the refrigerator and 
> allow KESIMPTA to reach room temperature for about 15 to 30 minutes. DO NOT remove the needle cover while 
> allowing the prefilled syringe to reach room temperature. 
> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, 
> whenever solution and container permit. Do not use if the liquid contains visible particles or is cloudy.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
